ALK (C26G7) Rabbit mAb (Biotinylated)Product information
ALK (C26G7) Rabbit mAb (Biotinylated)
|100 µl (10 western blots)||-||Unavailable in your region|
Product Pathways - Tyrosine Kinase / Adaptors
ALK (C26G7) Rabbit mAb (Biotinylated) #8895
|8895S||100 µl (10 western blots)||---||In Stock||---|
|8895||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human||Endogenous||80 (NPM-ALK), 220 (ALK)||Rabbit IgG|
Applications Key: W=Western Blotting
Specificity / Sensitivity
ALK (C26G7) Rabbit mAb (Biotinylated) detects endogenous levels of total ALK protein. This antibody does not cross-react with other family members.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant fusion protein surrounding His1475 of human ALK protein.
This Cell Signaling Technology antibody is conjugated to biotin under optimal conditions. The biotinylated antibody is expected to exhibit the same species cross-reactivity as the unconjugated ALK (C26G7) Rabbit mAb #3333.
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor for pleiotrophin (PTN), a growth factor involved in embryonic brain development (1-3). In ALK-expressing cells, PTN induces phosphorylation of both ALK and the downstream effectors IRS-1, Shc, PLCγ, and PI3 kinase (1). ALK was originally discovered as a nucleophosmin (NPM)-ALK fusion protein produced by a translocation (4). Investigators have found that the NPM-ALK fusion protein is a constitutively active, oncogenic tyrosine kinase associated with anaplastic lymphoma (4). Research literature suggests that activation of PLCγ by NPM-ALK may be a crucial step for its mitogenic activity and involved in the pathogenesis of anaplastic lymphomas (5).
A distinct ALK oncogenic fusion protein involving ALK and echinoderm microtubule-associated protein like 4 (EML4) has been described in the research literature from a non-small cell lung cancer (NSCLC) cell line, with corresponding fusion transcripts present in some cases of lung adenocarcinoma. The short, amino-terminal region of the microtubule-associated protein EML4 is fused to the kinase domain of ALK (6-8).
- Stoica, G.E. et al. (2001) J Biol Chem 276, 16772-9.
- Iwahara, T. et al. (1997) Oncogene 14, 439-49.
- Morris, S.W. et al. (1997) Oncogene 14, 2175-88.
- Morris, S.W. et al. (1994) Science 263, 1281-4.
- Bai, R.Y. et al. (1998) Mol Cell Biol 18, 6951-61.
- Rikova, K. et al. (2007) Cell 131, 1190-203.
- Takeuchi, K. et al. (2008) Clin Cancer Res 14, 6618-24.
- Soda, M. et al. (2007) Nature 448, 561-6.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.